Effect of nintedanib on lung function in patients with systemic sclerosis‐associated interstitial lung disease: further analyses of the SENSCIS trial

Post-hoc analysis (n=576) found that fewer patients given nintendanib had a decrease in FVC ≥3.3% predicted (proposed minimally clinically important difference for worsening FVC; 34.5% vs 43.8%), while more had an increase in FVC ≥3.0% predicted (23.0% vs 14.9%).

Source:

Arthritis & Rheumatology